Johnson & Johnson

Johnson & Johnson

Pharmaceuticals
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

$651.1B

Market Cap • 11/20/2026

1887

(139 years)

Founded

1944

(82 years ago)

IPO

NYSE

Listing Exchange

Flag of United States

United States

Country

S&P500 Participant

Index Composite • 2026

Valuation

P/B

8

P/S

6,6

P/EBITDA

19,6

P/OCF

24,9

P/FCF

31,6

P/E

41

BVPS

33,9

EPS

6,6

Market Cap

Market Cap

651,1B

EV

678,5B

EV/Revenue

6,8

EV/EBITDA

20,5

EV/EBIT

27,1

Payout

Dividend Per Share

5,3

Dividend Yield

2%

Buyback Yield

0,6%

Total Yield

2,6%

Dividend Yield 5Y

2,6%

Payout

79%

Retained Earnings

168,4B

Profitability

Gross Margin

67,6%

EBITDA Margin

33,4%

EBIT Margin

25,2%

Net Margin

16,2%

D&A/EBITDA

0%

R&D/Revenue

16,7%

Capex/Revenue

5,6%

Capex/D&A

68,8%

Capex/OCF

21,3%

SBC/OCF

5,4%

% PPE

12,2%

% Goodwill

24,6%

ROE

20%

ROIC

15,4%

Growth

CAGR Revenue 5Y

1,7%

CAGR Op. Income 5Y

1,9%

CAGR Net Income 5Y

-2,1%

CAGR EPS 5Y

-0,3%

CAGR OCF 5Y

0,1%

Leverage

N.D./EBITDA

0,8

Debt/Equity

0%

Current Ratio

1

Quick Ratio

0,7

Interest Coverage

2547,7%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium